[Use of lanreotide in the prevention of pancreatic fistula after cephalic duodeno-pancreatectomy. Preliminary study]

What Was Tested

The paper reports a study of Somatostatin and Lanreotide in the context of pancreatitis (after the acute phase), published as a clinical trial.

Dehiscence of pancreatic anastomosis is the main complication after pancreatoduodenectomy.

The aim of this preliminary prospective study was to assess the role of lanreotide (a long acting somatostatin analogue) in this field.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults.

Forty patients with pancreatic head tumour have been included in a prospective study.

Criteria for pancreatic fistula were: high concentration of amylase in the drainage fluid (> 3 times that in the serum), or intra-abdominal fluid collection adjacent to the pancreatic anastomosis, or reoperation (or postmortem verification) showing an anastomotic dehiscence.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Pancreatic Fistula, Pancreaticoduodenectomy, Peptides, Cyclic and Somatostatin.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Lanreotide in people with pancreatitis (after the acute phase).

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (Chirurgie; memoires de l'Academie de chirurgie), a journal based in France.

More context: the Somatostatin compound page and the Lanreotide compound page, Pancreatitis (after the acute phase) research.